Enliven Therapeutics (ELVN) Cash & Current Investments (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Cash & Current Investments data on file, last reported at $452.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 344.82% year-over-year to $452.4 million; the trailing twelve-month figure through Mar 2026 stood at $452.4 million (up 344.82% YoY), and the FY2025 full-year result was $462.6 million, up 47.59% from the prior year.
• Cash & Current Investments slipped to $452.4 million in Q1 2026, from $462.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $462.6 million in Q4 2025 to a low of $75.5 million in Q4 2022.
• A 5-year average of $210.8 million and a median of $136.3 million in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 68.27% in 2025 and jumped 344.82% in 2026, its largest moves.
• Tracing ELVN's Cash & Current Investments over 5 years: stood at $75.5 million in 2022, then surged by 235.14% to $253.1 million in 2023, then rose by 23.82% to $313.4 million in 2024, then jumped by 47.59% to $462.6 million in 2025, then decreased by 2.21% to $452.4 million in 2026.
• Business Quant data shows ELVN's Cash & Current Investments at $452.4 million in Q1 2026, $462.6 million in Q4 2025, and $101.7 million in Q3 2025.